Email
Print
Intestine (Small) Cancer Therapeutics Market - Forecast(2024 - 2030)
Intestine (Small) Cancer Therapeutics Market Overview
The burgeoning awareness regarding efficient cancer
treatment that includes early diagnosis and treatment initiation of ailments
such as adenocarcinoma, sarcoma and carcinoid tumors is set to drive the
Intestine (Small) Cancer Therapeutics Market. The greater per capita
expenditure on healthcare and the launch of novel oncological medications are set
to propel the growth of the Intestine (Small) Cancer Therapeutics Industry
during the forecast period 2022-2027. This represents the Intestine (Small)
Cancer Therapeutics Industry Outlook.
Intestine (Small) Cancer Therapeutics Market Report Coverage
The “Intestine (Small) Cancer
Therapeutics Market Report - Forecast (2022-2027)” by Industry ARC,
covers an in-depth analysis of the following segments in the Intestine (Small) Cancer
Therapeutics Market.
Key Takeaways
- Geographically, North America Intestine (Small) Cancer Therapeutics Market share accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027. This is because of the greatest per capita expenditure on healthcare involving carcinogenic treatments for ailments like adenocarcinoma, sarcoma and carcinoid tumors in the North American region.
- Intestine (Small) Cancer Therapeutics Market growth is being driven by the increasing predominance of Intestine (Small) Cancer and gastrointestinal stromal tumors across the world. However, nearly all developing countries are less exposed to progressive carcinogenic medicines and therapeutics. Also, the accessibility of more novel targeted therapies remains low. These are some of the major factors hampering the growth of the Intestine (Small) Cancer Therapeutics Market.
- Intestine (Small) Cancer Therapeutics Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Intestine (Small) Cancer Therapeutics Market report.
Intestine (Small) Cancer Therapeutics Market: Market Share (%) by Region, 2021
For More Details On this report - Request For Sample
Intestine (Small) Cancer Therapeutics Market Segment Analysis - by Treatment Option
The Intestine (Small) Cancer
Therapeutics Market based on treatment options can be further segmented into Surgery, Chemotherapy, Radiation Therapy,
Targeted Drug Therapy and Immunotherapy. The Surgery Segment
held the largest Intestine (Small) Cancer Therapeutics Market share in 2021.
This growth is owing to the increasing application of surgery for the treatment
of small intestine cancers. Different kinds of complicated conditions include adenocarcinoma, sarcoma, carcinoid tumors, gastrointestinal stromal tumors and intestinal
lymphomas. Most investigations record that surgical intervention like curative resection is possible in nearly 40-65% of cases for small bowel adenocarcinoma. In investigations pertaining to the detection of intestinal cardia metaplasia, the biopsy protocol involved 8 biopsies from the gastric cardia, 4 from upper cardio, 4 from lower cardio and 4 each from the gastric body and antrum. The growing application of biopsy to analyze any suspicious
tissue for signs of cancer is further propelling the growth of the Surgery segment.
Furthermore, the Chemotherapy segment is estimated to grow with the
fastest CAGR of 9.1% during the forecast period 2022-2027 owing to the growing
application of chemotherapy utilizing medications to halt the growth of cancer
cells, either by destroying the cells or by halting them from dividing.
Intestine (Small) Cancer Therapeutics Market Segment Analysis - by End-use Industry
The Intestine (Small) Cancer Therapeutics Market based on the end-use industry can be further segmented into Hospitals, Specialty Clinics, Home Healthcare and Others. The Hospitals Segment held the largest Intestine (Small) Cancer Therapeutics Market share in 2021. This growth is owing to the increasing inclination of patients towards hospitals for diagnosis of Intestine (Small) Cancers. Adenocarcinoma, Sarcoma, Carcinoid tumors, Gastrointestinal stromal tumors and Intestinal lymphomas may be treated in hospitals equipped with specialized healthcare equipment. According to Cleveland Clinic, of all the sarcoma cases treated in hospitals, the five-year survival rate of soft tissue sarcoma ranges from 15% for metastasized cancer (cancer that has spread to other parts of the body) to 81% for cancer that hasn’t spread. Hospitals like HCG Network and MAX Healthcare attend to cases of small intestine cancer. Survivor stories of lymphoma patients and stomach cancer patients are available on the HCG Network website. The presence of advanced infrastructure and the effortless availability of qualified & skilled physicians and multidisciplinary teams in hospitals are further propelling the growth of this segment.
Furthermore, the Specialty Clinics segment is
estimated to grow with the fastest CAGR of 8.3% during the forecast period 2022-2027, owing to the reduced
costs and the enhanced access to care that these clinics provide while
attending to long-lasting challenges
in utilization, access and cost of behavioral health care.
Intestine (Small) Cancer Therapeutics Market Segment Analysis - by Geography
The Intestine (Small)
Cancer Therapeutics Market based on geography can be further segmented into
North America, Europe, Asia-Pacific, South America and the Rest of the World. North
America (Intestine (Small) Cancer Therapeutics Market) held the largest Intestine (Small) Cancer Therapeutics Market share with 36% of the overall market in
2021. The growth of this region is driven by the increasing count of
cases of small intestine cancers. This results in greater demand for Intestine (Small) Cancer Therapeutics in
the North American region. Sarcoma of the small intestine is more typical in
men, at a comparatively young age. The existence of key players like Johnson
& Johnson in the U.S. and the
increasing count of cases of adenocarcinoma are further propelling the growth
of the Intestine (Small) Cancer Therapeutics Industry, thereby contributing to
the Intestine (Small) Cancer Therapeutics Industry Outlook in the North
American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the increasing predominance of gastrointestinal ailments and small intestine cancers in the Asia-Pacific region. The rising pervasiveness of intestinal lymphomas and T-cell lymphomas are further fuelling the progress of the Intestine (Small) Cancer Therapeutics Market in the Asia-Pacific region.
Intestine (Small) Cancer Therapeutics Market Drivers
Soaring Treatments of Distinct Kinds of Digestive Tumors:
Adenocarcinoma of the Small Intestine is a rare tumor that can emerge in any portion of the Small Intestine that involves the duodenum, jejunum and ileum. Carcinoid tumor is rare in children and more typical in mature grown-ups. As per experts, carcinoid tumor influences 4 in 100,000 mature grown-ups. Carcinoid tumor in children and young adults is so rare that there is limited data on how many young people have them. The treatment options for Carcinoid Tumors include surgery, somatostatin analogs, targeted therapy and chemotherapy. Gastrointestinal stromal tumors form less than 1% of all digestive tract tumors. They can be benign or malignant (30%) and happen in each portion of the gastrointestinal tract. However, the stomach is the most typical localization. They establish identical prevalence in men and in women, mostly above the age of 50 years. The soaring treatments of distinct kinds of Digestive Tumors are therefore fuelling the growth of the Intestine (Small) Cancer Therapeutics Industry.
Surging Treatments of Intestinal Lymphomas in Developing Regions:
The Gastrointestinal (GI) tract is the most typical site of extranodal lymphoma being responsible for 30-40% of the cases. In Western nations, the stomach is the most typical site of GI lymphoma, while in the Middle East and Mediterranean nations, the small intestine is typically involved. Investigations have been conducted with the median age at diagnosis being 44 years and including predominantly males (85.45%). As per the American Cancer Society, cancers of the small intestine tend to happen more frequently in aged people. They are most frequently discovered in people in their 60s and 70s. While numerous lymphomas need chemotherapy or radiation therapy, the principal treatment protocol for small intestinal lymphoma is surgery. The favorable elimination of all cancerous tissue, essential for cancer to be "cured", relies considerably on the location and accessibility of the tumor(s). The surgery itself bears a hazard, with a stated mortality rate of under five percent. Of the patients who have the tumor favorably eliminated, the five-year survival rate is between 40 and 60 percent. The patient may have to accept a distinct diet permanently subsequent to the surgery to keep up suitable nutritional absorption. Radiotherapy and chemotherapy can also be imposed to clean up any outlying cancer cells or if surgery is unsuccessful or inconclusive. The surging treatments of Intestinal Lymphomas are therefore driving the growth of the Intestine (Small) Cancer Therapeutics Market during the forecast period 2022-2027.
Intestine (Small) Cancer Therapeutics Market Challenge
Difficulty in Detecting Intestine (Small) Cancer:
Though the small intestine constitutes the biggest portion of the gastrointestinal (GI) tract, small intestine cancers are rare in the U.S. In fact, they form the basis for less than 1 in 10 cancers of the gastrointestinal (GI) tract and less than 1 in 100 cancers on the whole. Small intestine cancer may be demanding to diagnose since it is very rare. Also, symptoms change relying on the kind of tumor. It may take extensive procedures and tests prior to accepting a diagnosis. These issues are thus hampering the growth of the Intestine (Small) Cancer Therapeutics Market.
Intestine (Small) Cancer Therapeutics Industry Outlook
Novel product launches, clinical trial pipelines, product approvals, patents, mergers and acquisitions, partnerships, alliances and financing in R&D are key strategies adopted by players in the Intestine (Small) Cancer Therapeutics Market. The top 10 companies in the Intestine (Small) Cancer Therapeutics Market are:
- F. Hoffmann La Roche Ltd.
- Novartis International AG
- Johnson & Johnson
- Bristol-Myers Squibb
- AstraZeneca Plc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals plc.
- Merck & Co. Inc.
- Sanofi S.A.
Recent Developments
- In March 2022, Novartis endorsed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to produce the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors. Under the terms of the initial agreement, the Carisma Therapeutics manufacturing process would be moved to the Novartis Cell Therapy Site in Morris Plains, the U.S, beginning in the coming days.
- In January 2021, Roche declared the CE-IVD introduction of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to assist in concluding the best treatment strategy for every patient.
- In October 2020, Roche Group gained biopharma firm Enterprise Therapeutics’ TMEM16A potentiator portfolio, established by its member Genentech. Enterprise’s shareholders accepted an upfront payment of £75m and are eligible to accept added milestone payments.
Relevant Reports:
Report Code: HCR 0405
Report Code: HCR 0197
Report Code: HCR 1186
For more Lifesciences and Healthcare Market reports, please click here